IN8bio Names Kate Rochlin, PhD Assistant Vice President Operations and Innovation
September 17, 2020 07:00 ET
|
IN8bio, Inc.
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by...
Incysus Therapeutics to Present at LifeSci Partners Summer Symposium
August 03, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
Incysus Therapeutics Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
May 28, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Initiates Enrollment in Phase 1 Study of a Genetically Modified Gamma-Delta (γδ) T Cell Immunotherapy in Patients with Newly Diagnosed Glioblastoma
February 27, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present at the New York Oncology Investor Conference
November 07, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present at 5th Annual CAR-TCR Summit
September 10, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Strengthens Board of Directors With Appointment of Pharmaceutical Veteran Peter C. Brandt
August 06, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Appoints Rozanna Yaing As Senior Vice President, Quality And Regulatory Affairs
July 02, 2019 08:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Announces Publication of U.S. Patent for Drug Resistant Immunotherapy (DRI) Technology
June 19, 2019 08:00 ET
|
Incysus Therapeutics, Inc.
US Patent and Trademark Office Issues U.S. Patent Covering Drug Resistant Immunotherapy (DRI) TechnologyClaims Provide Initial Protection for Incysus’ Novel DRI PlatformIncysus Controls Exclusive...
Incysus Therapeutics to Present at Jefferies 2019 Global Healthcare Conference
May 22, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...